Clinigen Group has expanded its Clinical Services (CS) business’ on-demand supply service with Accord Healthcare into France. Through the arrangement, Clinigen’s CS customers will continue to access the Accord portfolio, both UK and EU packs of product, for their clinical trials worldwide.
Clinigen’s CS business and Accord have been partners since 2012 in the delivery of oncology injectable products. The partnership was extended in 2019 to cover Accord’s European solid dose products, and to establish an on-demand supply service to Accord’s products. The on-demand supply service will now be operational in France as well as the UK, to service Clinigen’s global client base.
The CS team will be the point of contact for on-demand clinical trial supply enquiries. Customers can gain access to key products from Accord's generic oncology injectable product and solid dose product portfolio.
Earlier this year, Clinigen’s Global Access Business also extended its partnership with Accord for a further five years. This enabled it to continue to service health care professionals and their patients across the globe in the event of a supply chain disruption or drug shortage, providing unlicensed access to Accord’s portfolio.
Shaun Chilton, Group CEO of Clinigen, said: “Expanding our on-demand supply operations in Europe builds on our strong partnership with Accord. Having service operations in both the UK and in France enables us to service clients more efficiently across geographies. We know from experience that clients appreciate our ability to supply and distribute medicines across borders on an on demand basis, in a timely manner. Being able to supply both UK and European packs of Accord products provides even more flexibility to our clients running their clinical trials on a global basis.
“The span of the Accord partnership across two of our divisions is a good demonstration of the Clinigen business model and the synergies between divisions. It demonstrates how Clinigen can meet the needs of both pharma clients and healthcare professional customers on a global basis.”
Phill Semmens, Senior VP Commercial, Accord Healthcare, EMENA, said: “We have a strong partnership in place with Clinigen which continues to go from strength to strength. When we first established the ‘on demand’ service, it was the first of its kind for the pharma industry. By expanding its UK operations into France, Clinigen can ensure our products are even more accessible for use as comparator, co-therapy, rescue and adjunctive drugs in clinical trials. We look forward to continuing our work with the Clinigen team to serve our goal of benefitting treatment options for patients and broadening medical knowledge.”